Home |  Contact Us | Site Map

Latest News

All Releases
View Summary BioCryst to Present at Two Upcoming Investor Conferences
Nov 20, 2014
PDF 15.4 KB
View Summary BioCryst Reports Third Quarter 2014 Financial Results
Nov 6, 2014
PDF 30.3 KB
View Summary BioCryst to Announce Third Quarter 2014 Financial Results November 6
Oct 30, 2014
PDF 16.3 KB
View Summary RAPIVAB(TM) Trial Results for the Treatment of Influenza to be Presented at IDWeek 2014
Oct 8, 2014
PDF 18.0 KB
View Summary BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress
Oct 7, 2014
PDF 61.6 KB
View Summary BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases
Sep 18, 2014
PDF 20.9 KB
View Summary BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
Sep 6, 2014
PDF 18.7 KB
View Summary BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies
Sep 4, 2014
PDF 18.0 KB
View Summary BioCryst to Present at Rodman & Renshaw Conference
Sep 3, 2014
PDF 15.0 KB
View Summary BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
Sep 2, 2014
PDF 18.1 KB
View Summary BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola Virus Disease
Aug 29, 2014
PDF 17.3 KB
View Summary BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases
Aug 13, 2014
PDF 18.2 KB
View Summary BioCryst Reports Second Quarter 2014 Financial Results
Aug 5, 2014
PDF 31.1 KB
View Summary BioCryst to Announce Second Quarter 2014 Financial Results August 5
Jul 22, 2014
PDF 16.1 KB
View Summary BioCryst Announces Exercise of Over-Allotment Option and Completion of Public Offering
Jun 3, 2014
PDF 15.1 KB
View Summary BioCryst to Present at Two Upcoming Investor Conferences
Jun 2, 2014
PDF 15.3 KB
View Summary BioCryst Pharmaceuticals Prices Public Offering of Common Stock
May 28, 2014
PDF 18.5 KB
View Summary BioCryst Commences Public Offering of Common Stock
May 27, 2014
PDF 17.5 KB
View Summary BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 for the Prophylactic Treatment of Hereditary Angioedema
May 27, 2014
PDF 67.3 KB
View Summary BioCryst to Announce Results From the BCX4161 OPuS-1 Phase 2 Trial for Hereditary Angioedema May 27
May 24, 2014
PDF 17.3 KB
Showing 1-20 of 143 Page: 1 2 3 ... 8  Next 20